Arcus Biosciences, Inc. (RCUS)


-0.23 (-1.33%)
Symbol RCUS
Price $17.06
Beta 0.812
Volume Avg. 0.84M
Market Cap 1.320B
Shares () -
52 Week Range 15.7-36.13
1y Target Est -
DCF Unlevered RCUS DCF ->
DCF Levered RCUS LDCF ->
ROE -44.80% Strong Sell
ROA -23.15% Sell
Operating Margin -
Debt / Equity 10.07% Neutral
P/E -4.50 Strong Sell
P/B 2.21 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest RCUS news

Dr. Terry J. Rosen Ph.D.
New York Stock Exchange

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.